LONDON -(Dow Jones)- Sanofi-Aventis S.A.'s (SNY) anti-obesity pill Acomplia has been linked to five deaths and 720 adverse reaction since its U.K. launch in 2006, according to a document posted on the U.K. drug regulator’s website Tuesday. One of the deaths was due to suicide, said the Medicines and Healthcare products Regulatory Agency, or MHRA, document, which recorded adverse side effects up until May 9.
